Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir

Antiviral Therapy

Volumn 6, Issue 1, 2001, Pages 47-54

  Walmsley, Sharon L ^a   Becker, Mark I ^b   Zhang, Min ^b   Humar, Atul ^a   Harrigan, P Richard ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b AGOURON PHARMACEUTICALS INC   (United States)

^c Brit Columbia Ctr Excell HIV/AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NELFINAVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG EFFECT; FEMALE; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; SALVAGE THERAPY; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MALE; NELFINAVIR; RNA, VIRAL; SALVAGE THERAPY;

EID: 0035288025     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Annals of Internal Medicine 1997; 126:939-945.
2. Staszewski S, Miller V, Sabin C, Carlebach A, Berger A, Weidmann E, Helm E, Hill A & Phillips A. Virologic response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999; 13:367-373.
3. Selik RM, Karon JM & Ward JW. Effects of the human immunodeficiency epidemic on mortality from opportunistic infections in the United States in 1993. Journal of Infectious Diseases 1997; 176:632-636.
4. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schecter MT & Montaner JS. Decline in deaths from AIDS to new antiretrovirals. The Lancet 1997; 349:1294.
5. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD & the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338:853-860.
6. Wit F, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, Schuijtemaker J, Eyssen X, Fortuin D, Weeda M, de Wolf F, Reiss P, Danner S & Lange JMA. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. Journal of Infectious Diseases 1999; 79:790-798.
7. Fätkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, Wieland U, Pfister H, Reiser M, Hegener P, Franzen C, Scwenk A & Salzberger B. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients AIDS 1997; 11:F113-F116.
8. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emmi EA, Isaacs R, Chodakewitz JA & Richman DD. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. Journal of the American Medical Association 1998; 280:35-41.
9. Mehta S, Moore RD & Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997; 11:1665-1670.
10. Hoetelmans R, Reijers M, Weverling GJ, ten Kate RW, Wit FWNM, Mulder JW, Weigel HM, Jos Frissen PH, Roos M, Jurriaans S, Schuitemaker H, de Wolf F, Beijnen JH & Lange JMA. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998; 2:F111-F115.
11. Lafeuillade A, Chollet L, Hittinger G, Profiz N, Costes O & Poggi C. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL. Journal of Infectious Diseases 1998; 177:235-238.
12. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires K, Deutsch PJ & Emini EA. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569-571.
13. Cohen J. The daunting challenge of keeping HIV suppressed. Science 1997; 277:32-33.
14. Moyle GJ. Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choices. Expert Opinion on Investigational Drugs 1997; 6:943-964.
15. Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, Miller V & Larder BA. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 2000; 14:1203-1210.
16. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J & Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998; 12:F97-F102.
17. Craig C, Race E, Sheldon J, Whittaker L, Gilbert S, Moffatt A, Rose J, Dissanayeke S, Chirn G, Duncan IB & Cammack N. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS 1998; 12:1611-1618.
18. Mocroft A, Gill MJ, Davidson W & Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12:2161-2167.
19. Race E, Gilbert SM, Sheldon JG, Rose JSL, Moffatt AR, Sitbon G, Dissanayeke SR, Cammack N & Duncan IB. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. AIDS 1998: 12:1465-1474.
20. Schapiro JM, Winters MA, Lawrence J & Merigan TC. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS 1999; 13:359-365.
21. Mayers DL, Baxter JD, Wentworth DN, Neaton JD, Merigan TC & the CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The impact of drug resistance mutations in plasma virus of patients failing on protease inhibitor-containing HAART regimens on subsequent virological response to the next HAART regimen: results of CPCRA 046 (GART). Antiviral Therapy 1999; 4(Suppl. 1):51.
22. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JPA, Merigan TC & the CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14:F83-F93.
23. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montague N, Boucher CA, Shapiro JM & Dellamonica P. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. The Lancet 1999; 353:2195-2199.
24. th Conference on Retroviruses and Opportunistic Infections. San Francisco: Foundation for Retrovirology and Human Health, 2000: 120:Abstr. 237.
25. Zhang L, Ramratnam B, Tenner-Racz, He Y, Vesanen M, Lewein S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M & Ho DD. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. New England Journal of Medicine 1999; 340:1605-1613.
26. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS & Wolinsly SM. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. New England Journal of Medicine 1999; 340:1614-1622.
27. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA and Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 1997; 337:734-739.
28. Notermans DW, Jurriaans S, de Wolf F, Foudraine NA, de Jong JJ, Cavert W, Schuwirth CM, Kauffmann RH, Meenhorst PL, McDade H, Goodwin C, Leonard JM, Goudsmit J & Danner S for the Ritonavir/3TC/ZDV Study Group. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. AIDS 1998; 12:167-173.
29. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California: American Society for Microbiology, 1998; 433:Abstr. I-216.
30. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M & Lange JMA, for the INCAS Study Group. A randomized double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients, the INCAS trial. Journal of the American Medical Association 1998; 279:930-937.
31. Staszewski S, Morales-Ramirez J, Tashima K, Rachlis A, Skiest D, Stanford J, Striker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New England Journal of Medicine 1999; 341:1865-1873.
32. Rhone SA, Hogg RS, Yip B, Sherlock C, Conwawy B, Schechter MT, O'Shaughnessy MV & Montaner JSG. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998; 12:619-624.
33. th Conference on Retroviruses and Opportunistic Infections, Chicago: Foundation for retrovirology and Human Health, 1999; 159:Abstr. 489.
34. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freithmuth W, Snyder S, Mills C, Fischl M, Pettinelli C & Katzenstein D. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic vailure on indinavir: AIDS Clinical Trials Group Study 359. Journal of Infectious Diseases 2000; 182:1375-1384.
35. Lallemand F, Adda N, Schneider V, Jacomet C, Salhi Y & Rozenbaum W. Prospective follow-up of 67 indinavir experienced HIV/AIDS patients treated with ritonavir/saquinavir combination. Clinical Infectious Diseases 1999; 28:1184-1185.
36. Moyle G, Pozniak A, Opravil M, Clumeck N, Delfraissy JF, Johnson M, Pelgrom J, Reynes J, Vittecoq D, DeLora P, Salgo M & Duff F. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of prtoease inhibitor combinations in Europe. Journal of the Acquired Immune Deficiency Syndrome 2000; 23:128-137.
37. Para MF, Glidden DV, Coombs R, Collier A, Condra JH, Craig C, Bassette R, Leavitt R, Snyder S, McAuliffe V, Boucher C and the ACTG protocol 333 team. Baseline human immunodeficiecny type-1 phenotype, genotype and RNA response after switching from long-term hard capsule saquinivir to indinavir or soft-gel capsule saquinivir in ACTG protocol 333. Journal of Infectious Diseases 2000; 182:733-743.
38. Deeks S, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M & Volberding PA. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. Journal of Infectious Diseases 1999; 179:1375-1381.
39. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, Foundation for Retrovirology and Human Health 2000; 236. Abstr. LB7.
40. Tebas P, Patick AK, Kane EM, Klebert MK, Simpson JH, Erice A, Powderly WG & Henry K. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999; 13:F23-F28.
41. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi J & Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. Journal of the American Medical Association 2000; 283:229-234.
42. Zolopa A, Shafer R, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC & Efron B. HIV-1 genotypic resistance patterns predict response to saquinivir-ritonavir therapy in patients in whom previous protease inbhibitor therapy had failed. Annals of Internal Medicine 1999; 131:813-821.
43. Harrigan P, Hertogs K, Verbiest W, Pauwels R, Larder B, Kemp S, Bloor S, Yip B, Hogg R, Alexander C & Montaner JS. Baseline HIV resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13:1863-1871.
44. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Pemeger TV, Perrin L, Kaiser L & Yerly S. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999; 13:F17-F21.
45. Hirsch M, Brun-Vézinet, F,. D'Aquila R, Hammer S, Johnson V, Kuritzkes D, Loveday C, Mellors J, Clotet B, Conway B, Demeter, Vella S, Jacobsen D & Richman D. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an International AIDS Society-USA. Journal of the American Medical Association 2000; 283:2417-2426.
46. Monforte A, Testa L, Adorni F, Chiesa E, Bibi T, Moscatelli C, Abeli C, Rusconi S, Sollima S, Balotta C, Musicco M, Galli M & Moroni M. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998; 12:1631-1637.
47. Casado JL, Perez-Elías MJ, Antela A, Sabido R, Marti-Belda P, Drona F, Blazquez J & Quereda C. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998; 12:F131-F135.